Other languages Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Equities

TKD

JP3463000004

Real-time BOERSE MUENCHEN Other stock markets 11:30:04 25/06/2024 am IST			5-day change	1st Jan Change
24.51 ^EUR	+1.87%		-2.47%	-7.07%

24/06	Hutchmed China notes Takeda obtains EU approval for Fruzaqla	AN
24/06	Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24/06
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	24/06
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	24/06
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	24/06
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	24/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	22/06
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	22/06
Les sorcières épouvantent l'IA	21/06
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	21/06
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...	21/06
Borsa di Italia: Le streghe terrorizzano l'AI	21/06
Bolsa de Madrid: Las brujas aterrorizan a la IA	21/06
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India	21/06
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India	21/06
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India	21/06
Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	19/06
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS	19/06
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung	19/06
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	18/06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Equities

TKD

JP3463000004

Other languages

Filters